XML 27 R40.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segment Information (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Revenue $ 5,602.0 $ 5,602.0
Segment Reporting Information, Income (Loss) before Income Taxes 1,951.1 1,335.3
Income related to transfer of exenatide rights 495.4 0
Asset impairments, restructuring, and other special charges (21.7) (23.8)
Neuroscience [Member]
   
Segment Reporting Information, Revenue 1,848.8 1,903.7
Endocrinology [Member]
   
Segment Reporting Information, Revenue 1,724.9 1,690.9
Oncology [Member]
   
Segment Reporting Information, Revenue 764.2 803.9
Cardiovascular [Member]
   
Segment Reporting Information, Revenue 693.9 638.4
Animal health [Member]
   
Segment Reporting Information, Income (Loss) before Income Taxes 129.2 127.4
Segment Reporting Information, Revenue 499.1 490.7
Other pharmaceuticals [Member]
   
Segment Reporting Information, Revenue 71.1 74.4
Pharmaceutical products, total [Member]
   
Segment Reporting Information, Income (Loss) before Income Taxes 1,348.2 1,231.7
Segment Reporting Information, Revenue 5,102.9 5,111.3
Total segment [Member]
   
Segment Reporting Information, Income (Loss) before Income Taxes 1,477.4 1,359.1
Amylin [Member]
   
Income related to transfer of exenatide rights $ 495.4 $ 0